講題: **Mepolizumab in COPD: Real-World Case Sharing**
講者: 吳錦桐 醫師

演講摘要
隨著精準醫療與生物製劑的發展 COPD 治療正逐步邁入依據疾病表型與生物標記進行個人化治療的新時代 台灣臨床醫師亦開始累積 mepolizumab 應用於適合 COPD 病人的實務經驗 本場演講將透過真實世界病例分享 探討如何結合病人的急性惡化病史 嗜酸性白血球數值 臨床特徵與既有治療反應 辨識可能適合接受生物製劑治療的病人 並分享治療後在急性惡化 症狀控制及生活品質等面向的臨床觀察 此外 會議亦將整理 COPD 生物製劑的最新研究進展 促進臨床經驗交流 並共同探索更精準且個人化的疾病管理策略 期望為 COPD 病人帶來更完善的長期照護

With advances in precision medicine and biologic therapies, COPD management is entering a new era of personalized treatment guided by disease phenotypes and biomarkers. Clinicians in Taiwan are also beginning to accumulate practical experience with mepolizumab in appropriately selected patients with COPD. Through real-world case sharing, this session will explore how exacerbation history, blood eosinophil counts, clinical characteristics, and responses to existing therapies may support the identification of patients who could be considered for biologic treatment. Clinical observations following treatment, including changes in exacerbations, symptom control, and quality of life, will also be discussed. In addition, the session will review recent research developments in biologic therapies for COPD, facilitate the exchange of clinical experience, and explore more precise and individualized approaches to long-term disease management, with the goal of improving care for patients with COPD.

講題: **Beyond Inflammation Control:**

The Evolving Role of Nucala in Severe Asthma Management

講者:高定瑋 醫師

演講摘要

IL-5 與嗜酸性白血球在嚴重嗜酸性氣喘的 T2 發炎中扮演重要角色。Mepolizumab 為標靶 IL-5 的生物製劑 已累積降低急性惡化並改善疾病控制的臨床證據。隨著對嚴重氣喘病理機轉的認識持續深化 近期研究亦進一步探討 mepolizumab 對黏液栓塞, 上皮完整性及氣道重塑相關指標的潛在影響。本場演講將回顧 IL-5 在 T2 發炎中的角色 並分享 mepolizumab 從發炎控制到氣道病理及長期疾病管理的最新研究進展 協助臨床醫師更全面了解其在嚴重氣喘治療中的持續演進角色。

IL-5 and eosinophils play important roles in Type 2 inflammation in severe eosinophilic asthma. Mepolizumab, a biologic therapy targeting IL-5, has established clinical evidence in reducing exacerbations and improving disease control. As the understanding of severe asthma pathophysiology continues to evolve, emerging studies have further explored the potential impact of mepolizumab on mucus plugging, epithelial integrity, and airway remodeling-related parameters. This session will review the role of IL-5 in Type 2 inflammation and discuss recent evidence extending from inflammatory control to airway pathology and long-term disease management, providing a broader perspective on the evolving role of mepolizumab in the management of severe asthma.